[Effect of recombinant human interleukin-11 treatment on prognosis of patients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma].
Objective:To investigate the effects of recombinant human IL-11 treatment on prognosis of patients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma. Method:Seventy-eight cases of nasopharyngeal carcinoma patients were selected as the research object, all the patients were equally divided into observation group and control group with 39 cases in each group accorded to the random draw envelope principle. The control group received conventional chemoradiotherapy treatment, the observation group received the IL-11 treatment based on the treatment in control group, the treatment cycles in the two groups were 2 cycles. Result:After treatment, the total effective rates of the observation group and the control group were 87.2% and 59.0%, respectively, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). There were 14 cases of grade 0 radiation-induced oral mucositis, 6 cases of grade Ⅰ, 14 cases of grade Ⅱ, 5 cases of grade Ⅲ in the observation group during the treatment; There were 28 cases of grade 0 radiation-induced oral mucositis, 5 cases of grade Ⅰ, 4 cases of grade Ⅱ, 2 cases of grade Ⅲ in the control group during the treatment there was statistically significant difference between the two groups (P<0.05). After treatment, the serum CRP of observation group and control group were (5.32±1.92)mg/L and (12.44±2.48)mg/L that were significantly lower than before treatment of the (24.59±3.14)mg/L and (24.12±2.87)mg/L (P<0.05), serum levels of CRP after treatment in the observation group were significantly lower than the control group (P<0.05). After treatment, the pain scores of the observation group and the control group were significantly lower than those before treatment (P<0.05), and the pain scores of the observation group after treatment were significantly lower than the control group (P<0.05). Conclusion:The application of recombinant human IL-11 in the treatment of nasopharyngeal carcinom patients with radiochemoradiotherapy can decrease the expression of CRP, reduce the pain, relieve the oral mucositis and improve the prognosis.